首页> 外文OA文献 >Nanoparticles with high payloads of pipemidic acid, a poorly soluble crystalline drug: drug-initiated polymerization and self-assembly approach
【2h】

Nanoparticles with high payloads of pipemidic acid, a poorly soluble crystalline drug: drug-initiated polymerization and self-assembly approach

机译:具有高效载荷的纳米颗粒,一种可溶的结晶药物:药物引发的聚合和自组装方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nowadays, biodegradable polymers such as poly(lactic acid) (PLA), poly(D,L-lactic-co-glycolic acid) (PLGA) and poly(ε-caprolactone) (PCL) remain the most common biomaterials to produce drug-loaded nanoparticles (NPs). Pipemidic acid (PIP) is a poorly soluble antibiotic with a strong tendency to crystallize. PIP incorporation in PLA/PLGA NPs was challenging because of PIP crystals formation and burst release. As PIP had a poor affinity for the NPs, an alternative approach to encapsulation was used, consisting in coupling PIP to PCL. Thus, a PCL–PIP conjugate was successfully synthesized by an original drug-initiated polymerization in a single step without the need of catalyst. PCL–PIP was characterized by NMR, IR, SEC and mass spectrometry. PCL–PIP was used to prepare self-assembled NPs with PIP contents as high as 27% (w/w). The NPs were characterized by microscopy, DLS, NTA and TRPS. This study paves the way towards the production of NPs with high antibiotic payloads by drug-initiated polymerization. Further studies will deal with the synthesis of novel polymer–PIP conjugates with ester bonds between the drug and PCL. PIP can be considered as a model drug and the strategy developed here could be extended to other challenging antibiotics or anticancer drugs and employed to efficiently incorporate them in NPs. KEY WORDS: Pipemidic acid, Nanoparticle, Antibiotic, Nanoprecipitation, Crystalline drug, Drug-initiated   polymerization
机译:如今,可生物降解的聚合物如聚(乳酸)(PLA),聚(D,L-乳酸)(PLGGA)和聚(ε-己内酯)(PCL)仍然是产生药物的最常见的生物材料 - 负载纳米颗粒(NPS)。筛米酸(PIP)是一种可溶于抗生素,具有强烈的结晶倾向。由于皮晶体形成和爆发释放,PIP在PLA / PLGA NPS中的掺入是挑战性的。随着PIP对NPS具有较差的亲和力,使用替代的封装方法,包括在偶联PIP到PCL。因此,在没有催化剂的情况下在单一的一步中通过原始药物引发的聚合成功地合成PCL-PIP缀合物。 PCL-PIP的特征在于NMR,IR,SEC和质谱。 PCL-PIP用于制备具有高达27%(w / w)的pip含量的自组装nps。 NPS以显微镜,DLS,NTA和TRP为特征。本研究通过药物引发的聚合铺平了具有高抗生素有效载荷的NPS的生产。进一步的研究将处理与药物和PCL之间的酯键合成新的聚合物-IP缀合物。 PIP可以被认为是模型药物,这里开发的策略可以扩展到其他挑战性的抗生素或抗癌药物,并用于有效地将它们纳入NPS。关键词:铅酰酸,纳米粒子,抗生素,纳米沉淀,结晶药物,药物引发聚合

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号